Skip to main content

Jinling Pharmaceutical Company Limited (000919.SZ)

SHZ Healthcare Drug Manufacturers - Specialty & GenericView data quality →
51.8Fair

ValueMarkers Composite Index

Top 37%#28,337 of 44,714
Overvalued

117% above intrinsic value ($1)

UndervaluedFair ValueOvervalued
Piotroski
7/9
Strong
Beneish
-2.26
Low Risk
Altman
4.01
Safe
DCF Value
$1
Overvalued
ROIC
0.8%
Low
P/E
86.6
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Jinling Pharmaceutical Company Limited (000919.SZ) — VMCI valuation read

000919.SZ prints VMCI 52/100 inside the Healthcare sector, where the median sits at 50. The 2-point above-median delta is the cleanest single-number summary of Jinling Pharmaceutical Company Limited's composite stance, and in the mid-cap bucket it places the share ahead of the typical peer on the five-pillar mix.

On 000919.SZ, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.

**Investor frame.** 000919.SZ trades at 16.0x earnings, 11% below the Healthcare median of 18.0x; that is the value line. ROIC of 18.0% sits 8.0pp above the Healthcare median (10.0%); that is the quality line. net debt to EBITDA of 1.6x is the rate-sensitivity line to watch; that is the risk line for Jinling Pharmaceutical Company Limited on the trailing financials.

000919.SZ rose 0.2% over the trailing 7 days, with a +0.4% read on a 30-day basis.

Jinling Pharmaceutical Company Limited manufactures and sells pharmaceutical products in China. The company offers Mailuoning injection for the treatment of thrombo-occlusive vasculitis, arteriosclerotic occlusive disease, cerebral thrombosis and sequelae, multiple arteritis, acute arterial embolism of the limbs, diabetic gangrene, venous thrombosis, thrombophlebitis, etc.; ferrous succinate tablets for the prevention and treatment of iron deficiency anemia; and lentinan injection for treatment of malignant tumors. It also provides medical health care services. Jinling Pharmaceutical Company Limited is based in Nanjing, China.

CEO: Hai Chen5,789 employeesCNwww.jlyy000919.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in 000919.SZ’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.